View Clinical Trial (Medical Research Study)

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia - NCT01077375-06810(Clinical Trial 564201)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Danbury
State:  
CT
Zip Code: 06810
Conditions: Fibromyalgia
Purpose: The objective of this study is to evaluate the safety, tolerability and efficacy of milnacipran in patients with an inadequate response to duloxetine for the treatment of fibromyalgia.
Study summary: - Two weeks Duloxetine 60 mg Open-Label Period - Randomization to Double-Blind Treatment Period: 10 weeks Milnacipran (direct switch) or 10 weeks placebo (one week blinded 30 mg duloxetine) - One week Double-Blind Down-Taper Period
Criteria: Inclusion Criteria: - Diagnosis of fibromyalgia - Have been treated with a stable dosage of duloxetine (60 mg/day) for ≥ 4 weeks immediately before Screening (Visit 1) - Duloxetine must have been prescribed for the treatment of Fibromyalgia - Have a VAS 1-week pain recall score ≥ 40 mm and ≤ 90 mm - At Visit 2, to be eligible to enter the randomized treatment period, must continue to have a VAS 1-week pain recall score ≥ 40 mm and be dissatisfied with current Duloxetine treatment. Exclusion Criteria: - Suicidal risk - History of mania, bipolar disorder, psychotic disorder, schizophrenia, or a current episode of major depressive disorder - Myocardial infarction and/or stroke within the prior 6 months - Systolic blood pressure > 160 mm Hg or mean diastolic blood pressure > 100 mm Hg at Screening (Visit 1) - Substance abuse - Pulmonary dysfunction - Severe renal impairment - Active cardiac disease - Liver disease - Uncontrolled narrow-angle glaucoma - Autoimmune disease - Cancer - Inflammatory bowel disease - Unstable endocrine disease - Prostatic enlargement - Female patients who are pregnant or breastfeeding
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: September 22, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.